Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2014200479) MENIN-MLL INHIBITORS AND METHODS OF USE THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2014/200479 International Application No.: PCT/US2013/045417
Publication Date: 18.12.2014 International Filing Date: 12.06.2013
IPC:
A61K 31/445 (2006.01) ,A61P 35/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
445
Non-condensed piperidines, e.g. piperocaine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN [US/US]; 1600 Huron Parkway 2nd Floor Ann Arbor, Michigan 48109, US
VANDERBILT UNIVERSITY [US/US]; 305 Kirkland Hall 2201 West End Avenue Nashville, Tennessee 37240, US
Inventors:
GREMBECKA, Jolanta; US
CIERPICKI, Tomasz; US
UPADHYAY, Sunil Kumar; US
STAUFFER, Shaun R.; US
GOGLIOTTI, Rocco D.; US
SENTER, Timothy J.; US
Agent:
STAPLE, David W.; Casimir Jones, S.C. 2275 Deming Way Suite 310 Middleton, Wisconsin 53562, US
Priority Data:
Title (EN) MENIN-MLL INHIBITORS AND METHODS OF USE THEREOF
(FR) INHIBITEURS DE MÉNINE-MLL ET MÉTHODES D'UTILISATION ASSOCIÉES
Abstract:
(EN) The present invention relates generally to compounds that inhibit the binding of menin and MLL or MLL fusion proteins and methods of use thereof. In particular embodiments, the present invention provides compositions comprising piperdine-containing compounds and methods of use thereof to inhibit the interaction of menin with MLL oncoproteins (e.g., MLL1, MLL2, MLL-fusion oncoproteins), for example, for the treatment of leukemia, solid cancers, diabetes, and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, MLL-PTD and/or menin.
(FR) La présente invention concerne de manière générale des composés qui inhibent la liaison de la ménine et de la MLL ou de protéines de fusion de la MLL et des méthodes d'utilisation associées. Selon des modes de réalisation particuliers, la présente invention concerne des compositions comprenant des composés contenant une pipéridine et des méthodes d'utilisation associées pour inhiber l'interaction de la ménine avec des oncoprotéines MLL (ex. MLL1, MLL2, oncoprotéines de fusion avec la MLL), par exemple, pour le traitement de la leucémie, de cancers solides, de diabètes, et autres maladies dépendant de l'activité de la MLL1, de la MLL2, de protéines de fusion de la MLL, de la MLL-PTD et/ou de la ménine.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)